Yonsei Med J.  2006 Aug;47(4):443-454. 10.3349/ymj.2006.47.4.443.

The Genetic Studies of Obsessive-Compulsive Disorder and Its Future Directions

• Kim SJ
• Kim CH

• KMID: 1779492
• DOI: http://doi.org/10.3349/ymj.2006.47.4.443

Abstract

Obsessive-compulsive disorder (OCD) is characterized by recurrent and persistent thoughts (obsessions), and repetitive behaviors or mental acts (compulsions). In Korea, an epidemiological study reported that the lifetime prevalence of OCD in the population was greater than two percent. The exact cause of OCD is still unknown. Evidence from familial, twin and segregation studies supports the role of a genetic component in the etiology of OCD. In addition, there is growing evidence that OCD has a specific neurochemical and neuroanatomical basis. According to this evidence, researchers have selected various candidate genes which have been implicated in the neurophysiology of OCD, and differences of allelic variants in OCD patients and controls have been analyzed. In this review we will introduce the results of previous genetic studies of OCD which have been performed in other populations, including twin studies, family studies, segregation analyses, linkage analyses, and association studies. In addition to these studies, we will present the results of our genetic studies of OCD performed in Korea.

Keyword

Obsessive-compulsive disorder; genetic component

MeSH Terms

Variation (Genetics)
Serotonin/genetics
Obsessive-Compulsive Disorder/*genetics
Neurotransmitter Agents/genetics
Linkage (Genetics)
Humans
*Genetic Predisposition to Disease
Family Health
Dopamine/metabolism
Alleles

Reference

1. Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988; 45:1094–1099. PMID: 3264144.

2. Lee JK. A nationwide epidemiological study of mental disorders in Korea (XIII)-obsessive-compulsive disorder. J Korean Neuropsychiatr Assoc. 1994; 33:5–17.

3. Wolff M, Alsobrook JP 2nd, Pauls DL. Genetic aspects of obsessive-compulsive disorder. Psychiatr Clin North Am. 2000; 23:535–544. PMID: 10986726.

4. Inouye E. Similar and dissimilar manifestations of obsessive-compulsive neuroses in monozygotic twins. Am J Psychiatry. 1965; 121:1171–1175. PMID: 14286051.

5. Carey G, Gottesman II. Klein D, Rabkin J, editors. Twin and family studies of anxiety, phobic, and obsessive disorders. Anxiety: new research and changing concept. 1981. New York: Raven Press;p. 117–136.

6. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991; 48:730–738. PMID: 1883256.

7. Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 1992; 7(Suppl 2):37–41. PMID: 1484177.

8. van Grootheest DS, Cath DC, Beekman AT, Boomsma DI. Twin studies on obsessive-compulsive disorder: a review. Twin Res Hum Genet. 2005; 8:450–458. PMID: 16212834.

9. Hemmings SM, Stein DJ. The current status of association studies in obsessive-compulsive disorder. Psychiatr Clin North Am. 2006; 29:411–444. PMID: 16650716.

10. Lewis A. Problems of obsessional illness. Proc Roy Soc Med. 1935; 29:325–336. PMID: 19990606.

11. Rasmussen SA, Tsuang MT. Clinical characteristics and famil history in DSM-III obsessive-compulsive disorder. Am J Psychiatry. 1986; 143:317–322. PMID: 3953865.

12. Riddle MA, Scahill L, King R, Hardin MT, Towbin KE, Ort SI, et al. Obsessive compulsive disorder in children and adolescents: phenomenology and family history. J Am Acad Child Adolesc Psychiatry. 1990; 29:766–772. PMID: 2228931.

13. Bellodi L, Sciuto G, Diaferia G, Ronchi P, Smeraldi E. Psychiatric disorders in the families of patients with obsessive-compulsive disorder. Psychiatry Res. 1992; 42:111–120. PMID: 1631248.

14. Pauls DL, Alsobrook JP, Goodman W, Rasmussen S, Leckman JF. A family study of obsessive-compulsive disorder. Am J Psychiatry. 1995; 152:76–84. PMID: 7802125.

15. Nestadt G, Samuels J, Riddle M, Bienvenu OJ 3rd, Liang KY, LaBuda M, et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry. 2000; 57:358–363. PMID: 10768697.

16. Fyer AJ, Lipsitz JD, Mannuzza S, Aronowitz B, Chapman TF. A direct interview family study of obsessive-compulsive disorder. I. Psychol Med. 2005; 35:1611–1621. PMID: 16219119.

17. Lipsitz JD, Mannuzza S, Chapman TF, Foa EB, Franklin ME, Goodwin RD, et al. A direct interview family study of obsessive-compulsive disorder. II. Contribution of proband informant information. Psychol Med. 2005; 35:1623–1631. PMID: 16219120.

18. Nestadt G, Lan T, Samuels J, Riddle M, Bienvenu OJ 3rd, Liang KY, et al. Complex segregation analysis provides compelling evidence for a major gene underlying obsessive-compulsive disorder and for heterogeneity by sex. Am J Hum Genet. 2000; 67:1611–1616. PMID: 11058433.

19. Hanna GL, Fingerlin TE, Himle JA, Boehnke M. Complex segregation analysis of obsessive-compulsive disorder in families with pediatric probands. Hum Hered. 2005; 60:1–9. PMID: 16088199.

20. Cavallini MC, Pasquale L, Bellodi L, Smeraldi E. Complex segregation analysis for obsessive compulsive disorder and related disorders. Am J Med Genet. 1999; 88:38–43. PMID: 10050965.

21. Cavallini MC, Bertelli S, Chiapparino D, Riboldi S, Bellodi L. Complex segregation analysis of obsessive-compulsive disorder in 141 families of eating disorder probands, with and without obsessive-compulsive disorder. Am J Med Genet. 2000; 96:384–391. PMID: 10898919.

22. Alsobrook JP II, Leckman JF, Goodman WK, Rasmussen SA, Pauls DL. Segregation analysis of obsessive-compulsive disorder using symptom-based factor scores. Am J Med Genet. 1999; 88:669–675. PMID: 10581488.

23. Nicolini H, Hanna GL, Baxter T, Schwartz J, Weisbecker K, Spence MA. Segregation analysis of obsessive-compulsive and associated disorders: preliminary results. Ursus Medicus. 1991; 1:25–28.

24. Weissbecker K, Baxter LR, Schwartz JM. Linkage analysis of obsessive-compulsive disorder. Cytogenet Cell Genet. 1989; 51:1105.

25. Hanna GL, Veenstra-VanderWeele J, Cox NJ, Boehnke M, Himle JA, Curtis GC, et al. Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. Am J Med Genet. 2002; 114:541–552. PMID: 12116192.

26. Willour VL, Yao Shugart Y, Samuels J, Grados M, Cullen B, Bienvenu OJ 3rd, et al. Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. Am J Hum Genet. 2004; 75:508–513. PMID: 15272418.

27. Shugart YY, Samuels J, Willour VL, Grados MA, Greenberg BD, Knowles JA, et al. Genomewide linkage scan for obsessive-compulsive disorder: evidence for susceptibility loci on chromosomes 3q, 7p, 1q, 15q, and 6q. Mol Psychiatry. 2006; 11:763–770. PMID: 16755275.

28. Hemmings SM, Kinnear CJ, Niehaus DJ, Moolman-Smook JC, Lochner C, Knowles JA, et al. Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2003; 13:93–98. PMID: 12650952.

29. Marazziti D, Rossi A, Gemignani A, Giannaccini G, Pfanner C, Milanfranchi A, et al. Decreased platelet 3H-paroxetine binding in obsessive-compulsive patients. Neuropsychobiology. 1996; 34:184–187. PMID: 9121618.

30. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry. 1987; 22:667–687. PMID: 3036259.

31. Pigott TA, Zohar J, Hill JL, Bernstein SE, Grover GN, Zohar-Kadouch RC, et al. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991; 29:418–426. PMID: 2018816.

32. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996; 66:2621–2624. PMID: 8632190.

33. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274:1527–1531. PMID: 8929413.

34. McDougle CJ, Epperson CN, Price LH, Gelernter J. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry. 1998; 3:270–273. PMID: 9672904.

35. Bengel D, Greenberg BD, Cora-Locatelli G, Altemus M, Heils A, Li Q, et al. Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder. Mol Psychiatry. 1999; 4:463–466. PMID: 10523819.

36. Kinnear CJ, Niehaus DJ, Moolman-Smook JC, du Toit PL, van Kradenberg J, Weyers JB, et al. Obsessive-compulsive disorder and the promoter region polymorphism (5-HTTLPR) in the serotonin transporter gene (SLC6A4): a negative association study in the Afrikaner population. Int J Neuropsychopharmacol. 2000; 3:327–331. PMID: 11343612.

37. Camarena B, Rinetti G, Cruz C, Hernandez S, de la Fuente JR, Nicolini H. Association study of the serotonin transporter gene polymorphism in obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2001; 4:269–272. PMID: 11602033.

38. Frisch A, Michaelovsky E, Rockah R, Amir I, Hermesh H, Laor N, et al. Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur Neuropsychopharmacol. 2000; 10:205–209. PMID: 10793323.

39. Walitza S, Wewetzer C, Gerlach M, Klampfl K, Geller F, Barth N, et al. Transmission disequilibrium studies in children and adolescents with obsessive-compulsive disorders pertaining to polymorphisms of genes of the serotonergic pathway. J Neural Transm. 2004; 111:817–825. PMID: 15206000.

40. Chabane N, Millet B, Delorme R, Lichtermann D, Mathieu F, Laplanche JL, et al. Lack of evidence for association between serotonin transporter gene (5-HTTLPR) and obsessive-compulsive disorder by case control and family association study in humans. Neurosci Lett. 2004; 363:154–156. PMID: 15172105.

41. Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L. Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J. 2002; 2:176–181. PMID: 12082589.

42. Kim SJ, Lee HS, Kim CH. Obsessive-compulsive disorder, factor-analyzed symptom dimensions and serotonin transporter polymorphism. Neuropsychobiology. 2005; 52:176–182. PMID: 16220023.

43. Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry. 2000; 5:32–38. PMID: 10673766.

44. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006; 78:815–826. PMID: 16642437.

45. Greenberg BD, Benjamin J, Martin JD, Keuler D, Huang SJ, Altemus M, et al. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacology (Berl). 1998; 140:434–444. PMID: 9888619.

46. Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 1992; 49:21–28. PMID: 1728249.

47. Enoch MA, Greenberg BD, Murphy DL, Goldman D. Sexually dimorphic relationship of a 5-HT2A promoter polymorphism with obsessive-compulsive disorder. Biol Psychiatry. 2001; 49:385–388. PMID: 11239910.

48. Walitza S, Wewetzer C, Warnke A, Gerlach M, Geller F, Gerber G, et al. 5-HT2A promoter polymorphism-1438G/A in children and adolescents with obsessive-compulsive disorders. Mol Psychiatry. 2002; 7:1054–1057. PMID: 12476319.

49. Meira-Lima I, Shavitt RG, Miguita K, Ikenaga E, Miguel EC, Vallada H. Association analysis of the catechol-o-methyltransferase (COMT), serotonin transporter (5-HTT) and serotonin 2A receptor (5HT2A) gene polymorphisms with obsessive-compulsive disorder. Genes Brain Behav. 2004; 3:75–79. PMID: 15005715.

50. Tot S, Erdal ME, Yazici K, Yazici AE, Metin O. T102C and -1438 G/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder. Eur Psychiatry. 2003; 18:249–254. PMID: 12927326.

51. Nicolini H, Cruz C, Camarena B, Orozco B, Kennedy JL, King N, et al. DRD2, DRD3 and 5HT2A receptor genes polymorphisms in obsessive-compulsive disorder. Mol Psychiatry. 1996; 1:461–465. PMID: 9154247.

52. Graf M. 5-HT2c receptor activation induces grooming behaviour in rats: possible correlations with obsessive-compulsive disorder. Neuropsychopharmacol Hung. 2006; 8:23–28. PMID: 16841562.

53. Cavallini MC, Di Bella D, Pasquale L, Henin M, Bellodi L. 5HT2C CYS23/SER23 polymorphism is not associated with obsessive-compulsive disorder. Psychiatry Res. 1998; 77:97–104. PMID: 9541145.

54. Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology. 2004; 50:200–205. PMID: 15365215.

55. Stern L, Zohar J, Cohen R, Sasson Y. Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan. Eur Neuropsychopharmacol. 1998; 8:325–328. PMID: 9928925.

56. Mundo E, Richter MA, Sam F, Macciardi F, Kennedy JL. Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am J Psychiatry. 2000; 157:1160–1161. PMID: 10873927.

57. Mundo E, Richter MA, Zai G, Sam F, McBride J, Macciardi F, et al. 5HT1Dbeta receptor gene implicated in the pathogenesis of obsessive-compulsive disorder: further evidence from a family-based association study. Mol Psychiatry. 2002; 7:805–809. PMID: 12192628.

58. Camarena B, Aguilar A, Loyzaga C, Nicolini H. A family-based association study of the 5-HT-1Dbeta receptor gene in obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2004; 7:49–53. PMID: 14731309.

59. Di Bella D, Cavallini MC, Bellodi L. No association between obsessive-compulsive disorder and the 5-HT (1Dbeta) receptor gene. Am J Psychiatry. 2002; 159:1783–1785. PMID: 12359689.

60. Lochner C, Hemmings SM, Kinnear CJ, Moolman-Smook JC, Corfield VA, Knowles JA, et al. Corrigendum to "gender in obsessive-compulsive disorder: clinical and genetic findings" [Eur. Neuropsychopharmacol. 14 (2004) 105-113]. Eur Neuropsychopharmacol. 2004; 14:437–445. PMID: 15468463.

61. Nielsen DA, Dean M, Goldman D. Genetic mapping of the human tryptophan hydroxylase gene on chromosome 11, using an intronic conformational polymorphism. Am J Hum Genet. 1992; 51:1366–1371. PMID: 1463016.

62. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003; 299:76. PMID: 12511643.

63. Mossner R, Walitza S, Geller F, Scherag A, Gutknecht L, Jacob C, et al. Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2006; 9:437–442. PMID: 16146581.

64. Stein DJ. The neurobiology of obsessive-compulsive disorder. Neuroscientist. 1996; 2:300–305.

65. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry. 1990; 51(Suppl):36–43. discussion 55-8. PMID: 2199433.

66. Agid O, Lerer B. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. J Clin Psychiatry. 1999; 60:55–56. PMID: 10074882.

67. Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry. 1992; 53:439–442. PMID: 1487472.

68. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 1992; 14:1104–1106. PMID: 1478653.

69. Miller GM, Madras BK. Polymorphisms in the 3'-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry. 2002; 7:44–55. PMID: 11803445.

70. Yoo SW, Kim SJ, Kim CH. Association between obsessive-compulsive disorder and dopamine transporter gene polymorphism. Psychiatry Invest. 2006; 3:72–77.

71. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 2001; 1:152–156. PMID: 11911442.

72. van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, et al. Multiple dopamine D4 receptor variants in the human population. Nature. 1992; 358:149–152. PMID: 1319557.

73. Billett EA, Richter MA, Sam F, Swinson RP, Dai XY, King N, et al. Investigation of dopamine system genes in obsessive-compulsive disorder. Psychiatr Genet. 1998; 8:163–169. PMID: 9800217.

74. Millet B, Chabane N, Delorme R, Leboyer M, Leroy S, Poirier MF, et al. Association between the dopamine receptor D4 (DRD4) gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2003; 116:55–59. PMID: 12497615.

75. Hemmings SM, Kinnear CJ, Lochner C, Niehaus DJ, Knowles JA, Moolman-Smook JC, et al. Early- versus late-onset obsessive-compulsive disorder: investigating genetic and clinical correlates. Psychiatry Res. 2004; 128:175–182. PMID: 15488960.

76. Kim SJ, Yoo SW, Nam YY, Lee HS, Kim CH. Association between obsessive-compulsive disorder and dopamine receptor D4. Korean J Psychopharmacol. 2005; 16:513–520.

77. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg H. Association between the dopamine D(2) receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur Neuropsychopharmacol. 2006; 16:446–450. PMID: 16427255.

78. Catalano M, Sciuto G, Di Bella D, Novelli E, Nobile M, Bellodi L. Lack of association between obsessive- compulsive disorder and the dopamine D3 receptor gene: some preliminary considerations. Am J Med Genet. 1994; 54:253–255. PMID: 7810583.

79. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996; 6:243–250. PMID: 8807664.

80. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995; 34:4202–4210. PMID: 7703232.

81. Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J, et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci U S A. 1997; 94:4572–4575. PMID: 9114031.

82. Karayiorgou M, Sobin C, Blundell ML, Galke BL, Malinova L, Goldberg P, et al. Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol Psychiatry. 1999; 45:1178–1189. PMID: 10331110.

83. Schindler KM, Richter MA, Kennedy JL, Pato MT, Pato CN. Association between homozygosity at the COMT gene locus and obsessive compulsive disorder. Am J Med Genet. 2000; 96:721–724. PMID: 11121168.

84. Niehaus DJ, Kinnear CJ, Corfield VA, du Toit PL, van Kradenburg J, Moolman-Smook JC, et al. Association between a catechol-o-methyltransferase polymorphism and obsessive-compulsive disorder in the Afrikaner population. J Affect Disord. 2001; 65:61–65. PMID: 11426511.

85. Erdal ME, Tot S, Yazici K, Yazici A, Herken H, Erdem P, et al. Lack of association of catechol-O-methyltransferase gene polymorphism in obsessive-compulsive disorder. Depress Anxiety. 2003; 18:41–45. PMID: 12900951.

86. Ohara K, Nagai M, Suzuki Y, Ochiai M, Ohara K. No association between anxiety disorders and catechol-O-methyltransferase polymorphism. Psychiatry Res. 1998; 80:145–148. PMID: 9754693.

87. Hotamisligil GS, Breakefield XO. Human monoamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet. 1991; 49:383–392. PMID: 1678250.

88. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet. 1998; 103:273–279. PMID: 9799080.

89. Camarena B, Rinetti G, Cruz C, Gomez A, de La Fuente JR, Nicolini H. Additional evidence that genetic variation of MAO-A gene supports a gender subtype in obsessive-compulsive disorder. Am J Med Genet. 2001; 105:279–282. PMID: 11353450.

90. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl). 2004; 174:530–538. PMID: 15083261.

91. Delorme R, Krebs MO, Chabane N, Roy I, Millet B, Mouren-Simeoni MC, et al. Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder. Neuroreport. 2004; 15:699–702. PMID: 15094479.

92. Zai G, Arnold P, Burroughs E, Barr CL, Richter MA, Kennedy JL. Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2005; 134:25–29. PMID: 15685626.

93. Hall D, Dhilla A, Charalambous A, Gogos JA, Karayiorgou M. Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. Am J Hum Genet. 2003; 73:370–376. PMID: 12836135.

94. Miguel EC, Leckman JF, Rauch S, do Rosario-Campos MC, Hounie AG, Mercadante MT, et al. Obsessive-compulsive disorder phenotypes: implications for genetic studies. Mol Psychiatry. 2005; 10:258–275. PMID: 15611786.